Slow-release oxprenolol compared with oxprenolol in hypertensive patients: A multicenter clinical trial

B. J. Materson; B. A. Friedman; K. M. Hla; B. S. Neidorf; J. M. Gray; N. Glazer; S. Gross

doi:10.1177/106002808301700115

Slow-release oxprenolol compared with oxprenolol in hypertensive patients: A multicenter clinical trial

B. J. Materson, B. A. Friedman, K. M. Hla, B. S. Neidorf, J. M. Gray, N. Glazer, S. Gross

Medicine

Research output: Contribution to journal › Article

1 Scopus citations

Abstract

Oxprenolol (OX) is a nonselective, β-adrenergic blocking agent with intrinsic sympathomimetic activity. We studied 178 patients in five centers to determine whether a polymer-matrix-based, slow-release preparation of oxprenolol (SR-OX) given once daily was as effective as the standard preparation given twice daily for the treatment of patients with mild to moderate hypertension. After a placebo washout phase, patients were treated with OX until blood pressure was controlled. They were then randomized in a double-blind fashion to continue the same dose, given as either OX bid or SR-OX qd with a placebo as the second dose. All patients took hydrochlorothiazide 50-100 mg/d throughout the study. Blood pressure was reduced 23/15 mm Hg (p < 0.001) and pulse 8 beats/min in the SR-OX group (n = 67), and 24/17 mm Hg (p < 0.001) and 8 beats/min in the OX group (n = 72) by titrating standard OX. After randomization to SR-OX or OX, there were no further changes over six weeks. Home-determined blood pressures showed no loss of control in the evening. There were no unexpected adverse effects. We conclude that SR-OX given once daily is as effective as OX given twice daily for the treatment of hypertension.

Original language	English (US)
Pages (from-to)	51-54
Number of pages	4
Journal	Unknown Journal
Volume	17
Issue number	1
DOIs	https://doi.org/10.1177/106002808301700115
State	Published - Jan 1 1983

Fingerprint

ASJC Scopus subject areas

Pharmacology, Toxicology and Pharmaceutics(all)
Pharmacology (medical)

Cite this

Materson, B. J., Friedman, B. A., Hla, K. M., Neidorf, B. S., Gray, J. M., Glazer, N., & Gross, S. (1983). Slow-release oxprenolol compared with oxprenolol in hypertensive patients: A multicenter clinical trial. Unknown Journal, 17(1), 51-54. https://doi.org/10.1177/106002808301700115

@article{2919f6ae238b4e779ddcd8f7528eeef6,

title = "Slow-release oxprenolol compared with oxprenolol in hypertensive patients: A multicenter clinical trial",

abstract = "Oxprenolol (OX) is a nonselective, β-adrenergic blocking agent with intrinsic sympathomimetic activity. We studied 178 patients in five centers to determine whether a polymer-matrix-based, slow-release preparation of oxprenolol (SR-OX) given once daily was as effective as the standard preparation given twice daily for the treatment of patients with mild to moderate hypertension. After a placebo washout phase, patients were treated with OX until blood pressure was controlled. They were then randomized in a double-blind fashion to continue the same dose, given as either OX bid or SR-OX qd with a placebo as the second dose. All patients took hydrochlorothiazide 50-100 mg/d throughout the study. Blood pressure was reduced 23/15 mm Hg (p < 0.001) and pulse 8 beats/min in the SR-OX group (n = 67), and 24/17 mm Hg (p < 0.001) and 8 beats/min in the OX group (n = 72) by titrating standard OX. After randomization to SR-OX or OX, there were no further changes over six weeks. Home-determined blood pressures showed no loss of control in the evening. There were no unexpected adverse effects. We conclude that SR-OX given once daily is as effective as OX given twice daily for the treatment of hypertension.",

author = "Materson, {B. J.} and Friedman, {B. A.} and Hla, {K. M.} and Neidorf, {B. S.} and Gray, {J. M.} and N. Glazer and S. Gross",

year = "1983",

month = jan

day = "1",

doi = "10.1177/106002808301700115",

language = "English (US)",

volume = "17",

pages = "51--54",

journal = "Scientific Computing and Instrumentation",

issn = "1078-8956",

publisher = "Springer Wien",

number = "1",

}

TY - JOUR

T1 - Slow-release oxprenolol compared with oxprenolol in hypertensive patients

T2 - A multicenter clinical trial

AU - Materson, B. J.

AU - Friedman, B. A.

AU - Hla, K. M.

AU - Neidorf, B. S.

AU - Gray, J. M.

AU - Glazer, N.

AU - Gross, S.

PY - 1983/1/1

Y1 - 1983/1/1

N2 - Oxprenolol (OX) is a nonselective, β-adrenergic blocking agent with intrinsic sympathomimetic activity. We studied 178 patients in five centers to determine whether a polymer-matrix-based, slow-release preparation of oxprenolol (SR-OX) given once daily was as effective as the standard preparation given twice daily for the treatment of patients with mild to moderate hypertension. After a placebo washout phase, patients were treated with OX until blood pressure was controlled. They were then randomized in a double-blind fashion to continue the same dose, given as either OX bid or SR-OX qd with a placebo as the second dose. All patients took hydrochlorothiazide 50-100 mg/d throughout the study. Blood pressure was reduced 23/15 mm Hg (p < 0.001) and pulse 8 beats/min in the SR-OX group (n = 67), and 24/17 mm Hg (p < 0.001) and 8 beats/min in the OX group (n = 72) by titrating standard OX. After randomization to SR-OX or OX, there were no further changes over six weeks. Home-determined blood pressures showed no loss of control in the evening. There were no unexpected adverse effects. We conclude that SR-OX given once daily is as effective as OX given twice daily for the treatment of hypertension.

AB - Oxprenolol (OX) is a nonselective, β-adrenergic blocking agent with intrinsic sympathomimetic activity. We studied 178 patients in five centers to determine whether a polymer-matrix-based, slow-release preparation of oxprenolol (SR-OX) given once daily was as effective as the standard preparation given twice daily for the treatment of patients with mild to moderate hypertension. After a placebo washout phase, patients were treated with OX until blood pressure was controlled. They were then randomized in a double-blind fashion to continue the same dose, given as either OX bid or SR-OX qd with a placebo as the second dose. All patients took hydrochlorothiazide 50-100 mg/d throughout the study. Blood pressure was reduced 23/15 mm Hg (p < 0.001) and pulse 8 beats/min in the SR-OX group (n = 67), and 24/17 mm Hg (p < 0.001) and 8 beats/min in the OX group (n = 72) by titrating standard OX. After randomization to SR-OX or OX, there were no further changes over six weeks. Home-determined blood pressures showed no loss of control in the evening. There were no unexpected adverse effects. We conclude that SR-OX given once daily is as effective as OX given twice daily for the treatment of hypertension.

UR - http://www.scopus.com/inward/record.url?scp=0020683196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020683196&partnerID=8YFLogxK

U2 - 10.1177/106002808301700115

DO - 10.1177/106002808301700115

M3 - Article

C2 - 6337801

AN - SCOPUS:0020683196

VL - 17

SP - 51

EP - 54

JO - Scientific Computing and Instrumentation

JF - Scientific Computing and Instrumentation

SN - 1078-8956

IS - 1

ER -

Access to Document

10.1177/106002808301700115